Uddalak Das,Soupayan Banerjee,Meghna Sarkar et al.
Uddalak Das et al.
Circular ribonucleic acid (circRNA) vaccines have emerged as a revolutionary strategy in cancer immunotherapy, facilitating novel approaches to induce robust and durable immune responses. Unlike traditional linear messenger RNA (mRNA) vacci...
Advances in nanoparticle-mediated cancer therapeutics: Current research and future perspectives [0.03%]
纳米颗粒介导的癌症治疗新进展：当前研究及未来前景
V C Deivayanai,P Thamarai,S Karishma et al.
V C Deivayanai et al.
One in six deaths worldwide is caused by cancer, making it a major global health concern. Despite their effectiveness, traditional treatment approaches such as radiation therapy, chemotherapy, and surgery frequently have negative side effec...
Weight management in overweight or obesity: Implications for cancer pathogenesis and prognosis [0.03%]
体重管理对肥胖或超重个体的癌症发病机制和预后的影响
Yue Wang,Haitao Niu,Peng Lyu et al.
Yue Wang et al.
An overview of randomized phase III clinical trials of cancer nanomedicines [0.03%]
癌症纳米药物随机三期临床试验概览
Micael N Melo,Ricardo G Amaral,Lucas R Melo de Andrade et al.
Micael N Melo et al.
Background: Cancer therapy has undergone significant advances in recent decades attributed to personalized medicine and targeted drug delivery. Among the promising approaches, the use of nano-based delivery systems has be...
Advanced molecular diagnostics: Driving precision in hematological malignancies [0.03%]
先进的分子诊断：推动血液系统恶性肿瘤的精准治疗
Li Bao,Xuechun Lu,Yaozhu Pan
Li Bao
Capmatinib treatment in a patient with osimertinib-resistant NSCLC harboring two distinct MET alterations revealed by tissue-based NGS testing [0.03%]
基于组织的下一代测序检测出奥西替尼耐药性NSCLC患者中两个不同的MET改变并接受卡马替尼治疗
Wirote Lausoontornsiri,Chek Kun Tan,Dimple Rajgor et al.
Wirote Lausoontornsiri et al.
Shaoxi Niu,Yaoguang Zhang,Hai Huang et al.
Shaoxi Niu et al.
Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease [0.03%]
多发性骨髓瘤相关骨骼病变多学科诊治专家共识
Yutong Wang,Qiming Xu,Yuan Li et al.
Yutong Wang et al.
This consensus on multiple myeloma-related bone diseases (MBDs) underscores the importance of a multidisciplinary approach that encompasses hematology, radiology, orthopedics, and additional specialties to tackle its intricate challenges. M...
Efficacy and safety of camrelizumab plus Lacticaseibacillus paracasei in the treatment of advanced esophageal squamous cell carcinoma: A single-arm, single-center, exploratory trial [0.03%]
卡瑞利珠单抗联合副干酪乳杆菌治疗晚期食管鳞癌的疗效和安全性：一项单臂、单中心探索性试验
Tengfei Zhang,Kang Cui,Xiaodan Liu et al.
Tengfei Zhang et al.
Background: Esophageal cancer (EC) is the seventh most prevalent cancer and the sixth most common cause of cancer-related mortalities worldwide. Camrelizumab, a monoclonal antibody, has demonstrated moderate efficacy in e...
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial [0.03%]
替西扎布生物类似药SIBP04与安维汀?一线治疗局部晚期或转移性非鳞状非小细胞肺癌的多中心、随机双盲III期临床试验：EFFLOW研究
Yuankai Shi,Minghong Bi,Qingshan Li et al.
Yuankai Shi et al.
Background: SIBP04 is a biosimilar of bevacizumab (Avastin®, Roche, Basel, Switzerland). This study evaluated the equivalence of SIBP04 to Avastin® as first-line treatment for locally advanced or metastatic non-squamous...